{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"21.0","value":"8.4"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"4.9","value":"4.1"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"3.9","value":"3.9"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"4.9","value":"3.9"},{"groupId":"OG004","lowerLimit":"1.4","upperLimit":"9.7","value":"6.8"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"12.5","value":"7.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"title":"Unconfirmed Duration of response (DOR), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"29.1","value":"11.3"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"4.9","value":"4.1"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"3.9","value":"3.9"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"4.9","value":"3.9"},{"groupId":"OG004","lowerLimit":"1.4","upperLimit":"12.5","value":"6.8"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"12.5","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"title":"Unconfirmed Duration of response (DOR), 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"21.0","value":"11.3"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"4.9","value":"4.1"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"3.9","value":"3.9"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"4.9","value":"3.9"},{"groupId":"OG004","lowerLimit":"2.4","upperLimit":"9.7","value":"7.6"},{"groupId":"OG005","lowerLimit":"8.1","upperLimit":"12.5","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Confirmed Duration of response (DOR), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"29.1","value":"12.7"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"4.9","value":"4.1"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"3.9","value":"3.9"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"4.9","value":"3.9"},{"groupId":"OG004","lowerLimit":"2.4","upperLimit":"12.5","value":"7.6"},{"groupId":"OG005","lowerLimit":"10.0","upperLimit":"12.5","value":"11.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Confirmed Duration of response (DOR), 36 months (DCO: Dec 11, 2020)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"description":"Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR was measured for responding subjects (PR or CR) only.","dispersionType":"Full Range","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.","id":"OG001","title":"Physician's Choice Irinotecan"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG002","title":"Physician's Choice Paclitaxel"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG003","title":"Physician's Choice Overall"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG004","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG005","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEDIAN","populationDescription":"Duration of response (DOR) was assessed in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 36 months postdose","title":"Duration of Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)","type":"SECONDARY","unitOfMeasure":"months"}